Kelsey Pan, MD, MPH, is a medical oncologist who specializes in caring for patients with lung cancer and other thoracic malignancies. Her practice is based at Winship Cancer Institute's Clifton and Midtown locations.
Dr. Pan is an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
She earned her medical degree and a Master of Public Health from the University of Miami Miller School of Medicine in Miami. She completed her internal medicine residency at the University of Florida in Gainesville, where she served as chief resident in her final year. She completed her hematology and oncology fellowship at The University of Texas MD Anderson Cancer Center in Houston, where she was chief fellow for two years.
Dr. Pan’s clinical and translational research focuses on non-small cell lung cancer (NSCLC), with particular interest in targeted therapies for oncogene-driven NSCLC, brain metastases and leptomeningeal disease. She has authored manuscripts in journals including Nature Reviews Clinical Oncology, Journal of Thoracic Oncology, and Cancer Cell and has presented her work at several national and international meetings. She has also participated in various workshops focused on clinical trial development, including AACR/ASCO Methods in Clinical Research, the FDA/ASCO Fellows’ Workshop and the EGFR Resisters Research Summit. Through leading innovative clinical trials, she aims to advance therapeutic strategies that improve outcomes and quality of life for patients with thoracic malignancies.
Titles & Roles
Assistant Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Education & Training
Education
Fellowship, Hematology/Oncology, 2025
MD Anderson Cancer Center
Residency, Internal Medicine, 2022
University of Florida College of Medicine
Medical Education, MD, 2018
University of Miami Leonard M. Miller School of Medicine
Board Certifications
Internal Medicine
American Board of Internal Medicine, 2021
Professional Memberships
International Association for the Study of Lung Cancer
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.
